The stock of Dynavax Technologies Corporation (NASDAQ:DVAX) is a huge mover today! About 3.18 million shares traded hands or 42.60% up from the average. Dynavax Technologies Corporation (NASDAQ:DVAX) has declined 25.67% since March 1, 2016 and is downtrending. It has underperformed by 34.91% the S&P500.
The move comes after 9 months negative chart setup for the $515.71M company. It was reported on Oct, 4 by Barchart.com. We have $10.36 PT which if reached, will make NASDAQ:DVAX worth $41.26M less.
Analysts await Dynavax Technologies Corporation (NASDAQ:DVAX) to report earnings on November, 3. They expect $-0.74 EPS, up 9.76% or $0.08 from last year’s $-0.82 per share. After $-0.75 actual EPS reported by Dynavax Technologies Corporation for the previous quarter, Wall Street now forecasts -1.33% EPS growth.
Dynavax Technologies Corporation (NASDAQ:DVAX) Ratings Coverage
Out of 2 analysts covering Dynavax Technologies (NASDAQ:DVAX), 0 rate it a “Buy”, 0 “Sell”, while 2 “Hold”. This means 0 are positive. Dynavax Technologies has been the topic of 4 analyst reports since August 12, 2015 according to StockzIntelligence Inc. The firm has “Outperform” rating given on Monday, November 30 by RBC Capital Markets. The stock of Dynavax Technologies Corporation (NASDAQ:DVAX) earned “Hold” rating by Zacks on Wednesday, August 12. RBC Capital Markets downgraded Dynavax Technologies Corporation (NASDAQ:DVAX) on Thursday, April 28 to “Sector Perform” rating. The firm earned “Neutral” rating on Wednesday, April 27 by JP Morgan.
According to Zacks Investment Research, “Dynavax Technologies discovers, develops, and intends to commercialize innovative products to treat and prevent allergies, infectious diseases, and chronic inflammatory diseases using versatile, proprietary approaches that alter immune system responses in highly specific ways. Dynavax’s clinical development programs are based on immunostimulatory sequences which are short DNA sequences that enhance the ability of the immune system to fight disease and control chronic inflammation.”
Insitutional Activity: The institutional sentiment decreased to 1.02 in Q2 2016. Its down 0.04, from 1.06 in 2016Q1. The ratio fall, as 18 funds sold all Dynavax Technologies Corporation shares owned while 34 reduced positions. 10 funds bought stakes while 43 increased positions. They now own 31.67 million shares or 4.27% less from 33.08 million shares in 2016Q1.
Reilly Fin Advisors Ltd has 0% invested in the company for 30 shares. Pictet Asset Management Ltd, a United Kingdom-based fund reported 246,492 shares. Cam Grp Incorporated Holding A S, a Denmark-based fund reported 189,962 shares. Blackrock Advsrs Ltd Llc accumulated 0% or 18,981 shares. Alliancebernstein L P holds 45,620 shares or 0% of its portfolio. Pnc Finance Gru Incorporated holds 160 shares or 0% of its portfolio. Clovis Capital Ltd Partnership holds 2.81% of its portfolio in Dynavax Technologies Corporation (NASDAQ:DVAX) for 416,397 shares. New Leaf Venture Prtnrs Lc last reported 5.71% of its portfolio in the stock. Blackrock Invest Management Ltd Limited Liability Company accumulated 147,646 shares or 0% of the stock. Geode Mgmt Lc, a Massachusetts-based fund reported 260,091 shares. Metropolitan Life Insur Ny owns 28,014 shares or 0% of their US portfolio. Earnest Limited Liability reported 850 shares or 0% of all its holdings. Mhr Fund Lc has 44,499 shares for 0.06% of their US portfolio. Rhenman & Prtn Asset Management Ab accumulated 150,000 shares or 0.39% of the stock. Blackrock Japan Comm Limited, a Japan-based fund reported 2,875 shares.
Insider Transactions: Since May 12, 2016, the stock had 2 insider buys, and 0 insider sales for $57,940 net activity. Shares for $42,820 were bought by Gray Eddie. 1,000 shares were bought by Janssen Robert, worth $15,120.
More recent Dynavax Technologies Corporation (NASDAQ:DVAX) news were published by: Investorplace.com which released: “Dynavax Technologies Corporation (DVAX) Steals Back Gains on Pending Heplisav …” on October 03, 2016. Also Investorplace.com published the news titled: “Dynavax Technologies Corporation (DVAX) Injected With 20%-Plus Gains” on September 06, 2016. Prnewswire.com‘s news article titled: “Shareholder Alert: Bronstein, Gewirtz & Grossman, LLC Announces Investigation …” with publication date: September 06, 2016 was also an interesting one.
DVAX Company Profile
Dynavax Technologies Corporation (Dynavax), incorporated on November 6, 2000, is a clinical-stage biopharmaceutical company. The Firm uses toll-like receptor (TLR) biology to discover and develop vaccines and therapeutics. The Company’s development programs are focused on vaccines and cancer immunotherapy. The Company’s lead vaccine product candidate is HEPLISAV-B, an investigational adult hepatitis B vaccine, which combines its TLR9 agonist adjuvant and recombinant hepatitis B surface antigen (rHBsAg). The Company’s lead cancer immunotherapy candidate is SD-101, a C Class CpG TLR9 agonist is selected for characteristics optimal for treatment of cancer, including high interferon induction. The Company’s SD-101 clinical program is intended to assess the preliminary efficacy of SD-101 in a range of tumors and in combination with a range of treatments. The Company’s advanced inflammatory disease candidate is AZD1419. The Company’s pipeline of product candidates for cancer immunotherapy includes DV281 and CpG-Nanoparticles, which are in the preclinical stage.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.